Instrument Inactif

Communiqués Cellmid Limited Australian S.E.

Actions

CDYDA

AU0000CDYDA5

Produits cosmétiques

Communiqués

03/10/24	Anagenics : 2024 Anagenics Annual Report	PU
05/12/22	Anagenics : FY2022 Annual Report	PU
26/07/22	Anagenics : Appendix 4C and Quarterly Activity Report	PU
28/04/22	Anagenics : Appendix 4C and Quarterly Activity Report	PU
09/12/21	Cellmid : AGM Presentation to Shareholders	PU
02/04/19	Cellmid : Alopecia Patent allowed in Europe	PU
26/03/19	Cellmid : Investor Newsletter March 2019	PU
21/02/19	Cellmid : Appendix 4D, Half Year Accounts and Strategy Update	PU
07/02/19	Cellmid : Significant New Findings Published On MIDKINE	PU
23/01/19	Cellmid : Appendix 4C and Notes to Appendix 4C	PU
21/12/18	Cellmid : Investor Newsletter - December 2018_Not announced on ASX	PU
12/12/18	Cellmid : CDY- Cellmid Expects Record Sales in Q2 FY2019	PU
19/11/18	Cellmid : CDY - Cellmid Appoints Exclusive New Zealand Distributor	PU
13/11/18	Cellmid : CDY - Change of Directors Interest Notice - Halasz	PU
13/11/18	Cellmid : CDY - Change of Directors Interest Notice - Eck	PU
25/09/18	Cellmid : Change of Director's Interest Notice_Bruce Gordon	PU
03/07/17	Nature Publication Identifies Cellmid Limited's Midkine as Important Target	AW
02/03/17	Cellmid : Cellmids FGF5 Inhibitor Clinical Study Published	PU
01/03/17	Cellmid : to Refinance R&D Loan Facility	PU
28/02/17	Cellmid : Appendix 4D and Half Year Accounts	PU
07/02/17	Cellmid : European Midkine Alopecia Patent Allowed	PU
31/01/17	Cellmid : USA Midkine Alopecia Patent Allowed	PU
31/01/17	Cellmid : Notes to Appendix 4C	PU
15/12/16	Cellmid : CxBladder update	PU
01/11/16	Cellmid : Appendix 3Y- Change of Director’s Interest Notice	PU